CSIMarket
 


Organogenesis Holdings Inc   (ORGO)
Other Ticker:  
 

Organogenesis Holdings Inc 's Long Term Debt to Equity

ORGO's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth




ORGO Long Term Debt to Equity (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change 35.5 % 42.18 % 54.63 % 65.68 % 188.93 %
Y / Y Long Term Debt Change -6.76 % 252.73 % 240.56 % 230.05 % 40.52 %
Long Term Debt to Equity MRQ 0.26 0.27 0.29 0.29 0.38
Overall Ranking # # # # #
Seq. Equity Change 0.76 % 4.59 % 0.49 % 27.94 % 5.73 %
Seq. Long Term Debt Change -1.98 % -1.29 % -1.27 % -2.38 % 270.78 %



Long Term Debt to Equity third quarter 2022 Comment
Due to long-term debt repayement of -1.98% Organogenesis Holdings Inc improved Long Term Debt to Equity in third quarter 2022 to 0.26, above company's average Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry Organogenesis Holdings Inc achieved lowest Long Term Debt to Equity. While total ranking remained unchanged compare to previous quarter at no. .

Explain Long Term Debt to Equity Ratio?
Learn more about ORGO
Long Term Debt to Equity Ratio ORGO on the trailing twelve month basis
Long Term Debt to Equity third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Organogenesis Holdings Inc 's Equity $ 256 Millions Visit ORGO's Balance sheet
Organogenesis Holdings Inc 's Long Term Debt $ 68 Millions Visit ORGO's Balance sheet
Source of ORGO's Sales Visit ORGO's Sales by Geography


Cumulative Organogenesis Holdings Inc 's Long Term Debt to Equity

ORGO's Long Term Debt to Equity for the trailling 12 Months

ORGO Long Term Debt to Equity

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth 35.5 % 42.18 % 54.63 % 65.68 % 188.93 %
Y / Y Long Term Debt TTM Growth -6.76 % 252.73 % 240.56 % 230.05 % 40.52 %
Long Term Debt to Equity TTM 0.28 0.3 0.27 0.24 0.2
Total Ranking TTM # # # # #
Seq. Equity TTM Growth 0.76 % 4.59 % 0.49 % 27.94 % 5.73 %
Seq. Long Term Debt TTM Growth -1.98 % -1.29 % -1.27 % -2.38 % 270.78 %


TTM Long Term Debt to Equity Comment
On the trailing twelve months basis Due to long-term debt repayement of -1.98% Organogenesis Holdings Inc decreased Long Term Debt to Equity in the III. Quarter to 0.28, above Organogenesis Holdings Inc 's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry ORGO recorded the lowest Long Term Debt to Equity. While total ranking remained unchanged compare to previous quarter at no. 0.

Explain Long Term Debt to Equity Ratio?
Learn more about ORGO
Long Term Debt to Equity Ratio ORGO on the trailing twelve month basis

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market # 0


TTM Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Long Term Debt to Equity in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Long Term Debt to EquitySep 30 2022 MRQ Long Term DebtSep 30 2022 MRQ Equity
Bioxcel Therapeutics Inc   0.72 $ 91.695  Millions$ 126.986  Millions
Emergent Biosolutions Inc   0.71 $ 1,032.100  Millions$ 1,449.300  Millions
Tg Therapeutics inc   0.70 $ 70.038  Millions$ 100.481  Millions
Innoviva Inc   0.69 $ 443.679  Millions$ 641.368  Millions
Ironwood Pharmaceuticals inc   0.67 $ 395.850  Millions$ 591.063  Millions
Merck and Co Inc   0.64 $ 28,482.000  Millions$ 44,524.000  Millions
Maravai Lifesciences Holdings Inc   0.62 $ 522.824  Millions$ 841.669  Millions
Trevena inc   0.61 $ 13.359  Millions$ 21.863  Millions
Opiant Pharmaceuticals Inc   0.60 $ 12.324  Millions$ 20.502  Millions
Axsome Therapeutics Inc   0.60 $ 93.913  Millions$ 157.361  Millions
Royalty Pharma Plc  0.59 $ 6,114.677  Millions$ 10,416.403  Millions
Vbi Vaccines Inc  0.58 $ 48.418  Millions$ 83.817  Millions
Rockwell Medical inc   0.56 $ 8.962  Millions$ 16.136  Millions
Cerevel Therapeutics Holdings Inc   0.56 $ 335.006  Millions$ 603.362  Millions
Harmony Biosciences Holdings inc   0.55 $ 189.725  Millions$ 343.884  Millions
Durect Corp  0.51 $ 17.928  Millions$ 34.854  Millions
Eton Pharmaceuticals Inc   0.51 $ 5.678  Millions$ 11.181  Millions
Horizon Therapeutics Public Limited Company  0.51 $ 2,549.140  Millions$ 5,033.687  Millions
Aptinyx Inc   0.51 $ 24.709  Millions$ 48.792  Millions
Assertio Holdings inc   0.49 $ 65.982  Millions$ 134.915  Millions
Pds Biotechnology Corp  0.49 $ 22.910  Millions$ 47.059  Millions
Cumberland Pharmaceuticals Inc   0.46 $ 17.700  Millions$ 38.491  Millions
Corbus Pharmaceuticals Holdings Inc   0.46 $ 19.269  Millions$ 41.946  Millions
Dynavax Technologies Corporation  0.44 $ 221.303  Millions$ 500.576  Millions
Tempest Therapeutics Inc   0.44 $ 11.836  Millions$ 26.773  Millions
Abbott Laboratories  0.43 $ 15,297.000  Millions$ 35,884.000  Millions
Verastem Inc   0.39 $ 24.667  Millions$ 62.873  Millions
Geron Corp  0.35 $ 37.799  Millions$ 108.172  Millions
Metacrine Inc   0.34 $ 12.580  Millions$ 37.065  Millions
Syros Pharmaceuticals Inc   0.31 $ 40.514  Millions$ 129.171  Millions

Date modified: 2022-11-13T02:23:21+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TEL's Profile

Stock Price

TEL's Financials

Business Description

Fundamentals

Charts & Quotes

TEL's News

Suppliers

TEL's Competitors

Customers & Markets

Economic Indicators

TEL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071